SynthesisSystematic reviews2012
Treatment of hyperprolactinemia: a systematic review and meta-analysis.
Synthesis in Systematic reviews, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 146 citations in OpenAlex.
- Quality of life in Prolactinoma: A systematic review.Pituitary · 2024Pooled it
- Dopamine agonists for preventing future miscarriage in women with idiopathic hyperprolactinemia and recurrent miscarriage history.The Cochrane database of systematic reviews · 2016Pooled it
- Chinese consensus on the diagnosis and treatment of prolactinomas (2025 edition).Chinese neurosurgical journal · 2026Review
- Incidence, Treatment Patterns, and Associated Clinical Conditions of Hyperprolactinemia Identified via Nationwide Claims Data in Korea: A 13-Year Population-Based Study.Journal of clinical medicine · 2026Article
- Identification of biomarkers associated with integrated stress response in pituitary adenomas based on bioinformatics.Discover oncology · 2026Article
- Hyperprolactinemia in Older Adults: A Narrative Review of Distinct Clinical Challenges and Management Strategies.Cureus · 2026Review
- The Emerging Role of Prolactin as a Biomarker for Reproduction, Health, and Welfare in Wildlife Species: Elephants as a Model.Advances in experimental medicine and biology · 2026Review
- Dopamine DCell death & disease · 2025Article
- Maternal heart failure: state-of-the-art review.Heart failure reviews · 2025Review
- Effects of cabergoline and dimethylcabergoline on the sexual behavior of male rats.Psychopharmacology · 2024Article
- Article
- Stem Cells and Infertility: A Review of Clinical Applications and Legal Frameworks.Journal of personalized medicine · 2024Review
- Prolactin-secreting pituitary adenomas: male-specific differences in pathogenesis, clinical presentation and treatment.Frontiers in endocrinology · 2024Review
- A Comprehensive Review of the Efficacy and Safety of Dopamine Agonists for Women with Endometriosis-associated Infertility from Inception to July 31, 2022.Acta medica Philippina · 2024Article
- Primary takotsubo syndrome with recurrent prolactinoma.Journal of cardiology cases · 2023Article
- Pediatric pituitary neuroendocrine tumors-a 13-year experience in a tertiary center.Frontiers in oncology · 2023Article
- Experience with Dopamine Agonists in the Treatment of Prolactinomas.Acta medica Lituanic · 2022Article
- Evaluation of hyperprolactinemia risk factors in infertile women referred to Yazd Infertility Center: A cross-sectional study.International journal of reproductive biomedicine · 2021Article
- Treatment of hyperprolactinemia: A single-institute experience.Journal of the Chinese Medical Association : JCMA · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyperprolactinemia is a common endocrine disorder that can be associated with significant morbidity. We conducted a systematic review and meta-analyses of outcomes of hyperprolactinemic patients, including microadenomas and macroadenomas, to provide evidence-based recommendations for practitioners. Through this review, we aimed to compare efficacy and adverse effects of medications, surgery and radiotherapy in the treatment of hyperprolactinemia.
methodsWe searched electronic databases, reviewed bibliographies of included articles, and contacted experts in the field. Eligible studies provided longitudinal follow-up of patients with hyperprolactinemia and evaluated outcomes of interest. We collected descriptive, quality and outcome data (tumor growth, visual field defects, infertility, sexual dysfunction, amenorrhea/oligomenorrhea and prolactin levels).
resultsAfter review, 8 randomized and 178 nonrandomized studies (over 3,000 patients) met inclusion criteria. Compared to no treatment, dopamine agonists significantly reduced prolactin level (weighted mean difference, -45; 95% confidence interval, -77 to -11) and the likelihood of persistent hyperprolactinemia (relative risk, 0.90; 95% confidence interval, 0.81 to 0.99). Cabergoline was more effective than bromocriptine in reducing persistent hyperprolactinemia, amenorrhea/oligomenorrhea, and galactorrhea. A large body of noncomparative literature showed dopamine agonists improved other patient-important outcomes. Low-to-moderate quality evidence supports improved outcomes with surgery and radiotherapy compared to no treatment in patients who were resistant to or intolerant of dopamine agonists.
conclusionOur results provide evidence to support the use of dopamine agonists in reducing prolactin levels and persistent hyperprolactinemia, with cabergoline proving more efficacious than bromocriptine. Radiotherapy and surgery are useful in patients with resistance or intolerance to dopamine agonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.